“…Moving away from model enrichments and display of platform capabilities, many research groups are now working on improving enzymes with industrial or medical relevance. [ 65 , 74 , 76 , 150 , 152 , 153 ] Besides the evolution of natural enzymes, the toolkit of directed evolution is expanding to artificial enzymes to introduce non‐natural reactivities urgently needed in the pharmaceutical industry, [152] de novo designed enzymes to understand and reengineer enzyme active sites, and, more recently, machine‐learning‐assisted directed evolution. [154] Furthermore, as fluorogenic substrates cannot always be synthesized, novel strategies for fast, but non‐fluorescence‐based detection will be critical for future developments.…”